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Background: Left ventricular diastolic dysfunction is one of the main characteristics of heart failure patients with a
preserved left ventricular ejection fraction. As bilirubin is regarded as an important endogenous antioxidant molecule,
serum total bilirubin levels were compared between heart failure patients with a preserved left ventricular ejection
fraction and normal controls in this study. We recruited 327 heart failure patients with a preserved left ventricular
ejection fraction and 200 healthy controls. Patients were divided into 4 subgroups by their comprehensive
echocardiographic manifestations, 1-mild, 2-moderate, 3-severe (reversible restrictive), 4-severe (fixed restrictive). Total
bilirubin levels were compared using stepwise multiple regressions adjusted for selected factors.
Results: After adjusting for gender, age, smoking, systolic blood pressure, diastolic blood pressure, total cholesterol and
triglyceride, serum total bilirubin levels were significantly lower in the heart failure group compared with the control
group (P < 0.01). Patients in the subgroup (4-severe) showed significantly (P < 0.05) lower levels of total bilirubin when
compared with the subgroup (1-mild).
Conclusions: TB level was negatively correlated with left ventricular diastolic dysfunction in heart failure patients with
a preserved left ventricular ejection fraction, which might provide a new insight into the complicated mechanisms of
heart failure with a preserved left ventricular ejection fraction.
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Bilirubin, once considered simply as the metabolic end-
product of heme degradation, has now emerged as an
important endogenous antioxidant molecule. Earlier re-
searches have demonstrated an inverse correlation between
serum bilirubin and the risk of coronary artery disease and
decreased antioxidant activity of bilirubin in atherosclerotic
lesions [1,2]. Recent studies have confirmed the correlation
between serum bilirubin levels and collateral development
in patients with chronic total coronary occlusion [3], periph-
eral arterial disease [4], amputation events in type-2 diabetes
mellitus [5], stroke severity and clinical outcomes [6]. Those
results suggested that bilirubin may be a part of a cell
defense strategy in those macro- and micro- angiopathies.* Correspondence: huanzi318@sohu.com
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stated.Heart failure with a preserved left ventricular ejection
fraction (HFpEF) is a clinical syndrome characterized by
the symptoms and signs of heart failure (HF), a preserved
left ventricular ejection fraction (LVEF ≥ 50%) and abnor-
mal diastolic function [7]. The percentage of patients with
HFpEF in epidemiological studies ranges from 40% to 71%
(mean 56%), but in hospital-based cohort studies it is
slightly lower, ranging from 24% to 55% (mean 41%) [8].
Despite the better LVEF, HFpEF has a prognosis similar to
that observed in HF patients with reduced LVEF, with a
mortality rate exceeding 20% in 1 year [9]. More and more
studies have suggested that chronic HF may be potentially
characterized as an oxidative disease [10-12]. Recently,
Radovanovic et al. showed that by-products of oxidative
damage and antioxidant enzyme activities were correlated
with echocardiographic indices of remodeling. After a long-
term follow-up, they found that the level of malondialde-
hyde, which was a biomarker of lipid peroxidation, mightLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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agement of chronic HF patients [13].
Diagnostically, echocardiography is an important tool
used to identify HFpEF and to stratify impaired diastolic
function according to its level of severity (mild, moderate
and severe) [14]. Multiple studies revealed a correlation
between the severity of diastolic dysfunction and risk of
death [15,16]. Unlike the association between serum total
bilirubin (TB) levels and vascular events, which has been
widely studied, whether or not TB plays a role in HFpEF
is not yet clear. This study was designed to determine
whether TB levels were significantly different in HFpEF
patients compared with controls and to investigate the
association between TB levels and echocardiographic
diastolic dysfunction grades.Results
Characteristics of all the HFpEF patients and healthy con-
trols were shown in Table 1. The 327 HFpEF patients were
categorized into four subgroups according to their compre-
hensive echocardiographic manifestations. The HFpEF
group included 130 males and 197 females with a mean age
of 66.8 ± 10.3 years, and the control group consisted of 116
males and 84 females with a mean age of 43.6 ± 9.7 years.
In the HFpEF group, 39.8% of the participants were male
and in the control group 58% were male (P < 0.01). Age,
body mass index, systolic blood pressure, diastolic blood
pressure, total cholesterol, low-density lipoprotein, trigly-
ceride and creatinine levels were all significantly greater in
the HFpEF group than in the control group (P < 0.05).
There were no differences between the two groups with
respect to high-density lipoprotein level, fasting glucose,
alanine aminotransferase and urea level (P > 0.05).
Since significant differences were found between the
HFpEF group and the control group for the association of
some variables and serum TB levels, differences in TB level
between the HFpEF and control group were examined after
adjusting for gender, age, smoking, systolic blood pressure,
diastolic pressure, total cholesterol and triglyceride. A sig-
nificantly lower serum level of TB was found in the HFpEF
group compared with the control group after adjustment
(P < 0.01). In addition, the level of TB was significantly
lower in patients with grade 4 than those with grade 1
disease (P < 0.05).
Simple linear regression and multivariate regression with
stepwise selection were used to evaluate factors associated
with TB level (Table 2). During the stepwise selection
process, we adopted the approach of bidirectional elimi-
nation, testing at each step for variables to be included or
excluded (αin = 0.05, αout = 0.10). Results showed that
gender, age and diastolic dysfunction echocardiographic
grading were significantly associated with TB level (R2 =
0. 261, P < 0.05).Discussion
In this study, none of the HFpEF patients had any relevant
diseases that could reduce the serum TB level, and we found
that serum TB levels were significantly lower in HFpEF pa-
tients than those in normal controls after adjusting for age,
gender, body mass index, smoking, systolic blood pressure,
diastolic blood pressure, total cholesterol and triglyceride. In
addition, the serum TB levels in HFpEF grade 4 (severe,
fixed restrictive) was significantly lower than those in HFpEF
grade 1 (mild). Last but not least, HFpEF echocardiophic
grading was significantly associated with serum TB levels in
simple linear regression and multivariate regression analysis.
Pathophysiology of HFpEF
Recent epidemiological studies have provided growing rec-
ognition that HFpEF is a common and costly clinical entity
that is increasing in prevalence [8,9]. The pathophysiology
of HFpEF is distinct from that of HF with reduced LVEF
and is characterized by left ventricular (LV) diastolic dys-
function [17]. Echocardiography is an essential non-invasive
tool useful for diagnosing and classifying LV diastolic
dysfunction. A key component of LV diastolic dysfunction is
LV stiffness causing inability to dilate sufficiently to cope
with the venous supply from the lungs. This stiffness can be
increased by any pathological process affecting the heart
muscle, the most common causes being LV hypertrophy
and/or myocardial ischemic lesions [18]. In addition, stiff-
ness is aggravated by changes in extracellular matrix colla-
gen deposition, and this can even precede LV hypertrophy
[19]. Meanwhile, it has been pointed out that free radicals
can be involved in cardiomyocyte hypertrophy, apoptosis
and mechanisms of cardiac remodeling [10,11]. Giordano
supported the concept of reactive oxygen species contrib-
uting to the cardiac remodeling processes in a number of
ways, including activating matrix metalloproteinases that
participate in reconfiguration of the extracellular matrix,
acting as signaling molecules in the development of com-
pensatory hypertrophy and myocyte loss via apoptosis or
other cell death mechanisms. The role of oxidative stress in
LV diastolic dysfunction is very complex and those concrete
pathways are still unclear; however, existence of systemic
oxidative stress in chronic HF and its gradual increase as
chronic HF progresses have been confirmed [13]. In recent
years, the improved treatment strategy has increased sur-
vival rate in systolic HF, whereas the prognosis for HFpEF
remains unchanged [9]. Risk stratification is an integral part
of management in patients with HFpEF, and is also an
important step in defining the optimal treatment strategy.
This is why researches are searching for new biomarkers to
help probe the complicated pathophysiology of HFpEF.
Antioxidant effects of TB
Since the report in 1994 by Schwertner et al. which indi-
cated that serum bilirubin level was negatively correlated









restrictive) (n = 138)
4-severe (fixed
restrictive) (n = 21)
P*-value
Male (n, %) 116 (58%) 31 (5.6%)a 44 (37.9%)a 49 (35.5%)a 6 (28.6%)a,b,c,d 0.003
Age (years) 43.6 (9.7) 69.7 (7.3)a 65.9 (10.2)a 67.1 (11.4)a 66.3 (13.1)a 0.001
BMI (kg/m2) 22.7 (2.5) 24.3 (3.6)a 23.9 (4.7) 24.5 (2.1)a 23.8 (3.7) 0.048
Smoker (n, %) 85 (42.5%) 25 (48.1%) 39 (33.6%) 38 (27.5%)a 5 (23.8%)a,b,c 0.028
Medications
ASA (n, %) 0 48 (92.3%)a 110 (94.8%)a 134 (97.1%)a 20 (95.2%)a <0.001
Diuretic (n, %) 0 21 (40.4)a 64 (55.2%)a,b 70 (50.7%)a,b 18 (85.7%)a,bc,d <0.001
Beta blocker (n, %) 0 21 (40.4%)a 44 (37.9%)a 50 (36.2%)a 8 (38.1%)a <0.001
ACEI/ARB (n, %) 0 47 (90.4%)a 112 (96.6%)a 133 (96.4%)a 21 (100%)a <0.001
Statin (n, %) 0 50 (96.2%)a 111 (95.7%)a 132 (95.7%)a 19 (90.5%)a <0.001
CCB (n, %) 0 27 (51.9%)a 52 (44.8%)a 66 (47.8%)a 9 (42.9%)a <0.001
HR (b/min) 77.4 (6.1) 75.8 (6.7) 78.2 (7.1) 71.1 (5.8)a 80.2 (7.2)d 0.036
SBP (mmHg) 120.1 (8.6) 124.6 (5.8) 138.1 (10.1)a,b 140.2 (9.3)a,b 150.6 (7.2)a,b,c 0.005
DBP (mmHg) 78.2 (7.0) 80.3 (8.8) 81.2 (6.5) 90.2 (10.3)a,b,c 91.4 (9.5)a,b,c 0.017
Total cholesterol (mg/dl) 191.7 (19.1) 209.3 (20.2)a 234.7 (19.0)a 225.6 (18.8)a 242.5 (22.7)a 0.007
LDL (mg/dl) 108.3 (17.4) 124.1 (18.2)a 120.6 (19.1)a 125.7 (18.8)a 131.9 (21.2)a 0.004
HDL (mg/dl) 51.3 (7.5) 43.4 (8.2) 44.0 (8.1) 47.9 (6.3) 45.2 (7.7) 0.069
Triglyceride (mg/dl) 128.8 (19.4) 150.9 (17.3)a 152.6 (18.4)a 147.6 (20.5)a 144.1 (19.6)a 0.025
Fasting glucose (mg/dl) 95.2 (7.3) 96.3 (8.1) 100.7 (6.8) 94.9 (7.4) 102.5 (8.2) 0.326
Creatinine (umol/L) 83.6 (10.7) 92.4 (11.1) 95.3 (9.6) 121.3 (12.5)a,b,c 127.6 (13.5)a,b,c 0.013
Urea level (umol/L) 261.4 (23.9) 252.4 (22.1) 274.5 (19.3) 282.6 (20.7) 288.2 (21.6) 0.204
Alanine aminotransferase (U/L) 25.4 (6.4) 32.1 (7.9) 29.6 (8.1) 30.1 (6.4) 32.1 (7.5) 0.338
TB (umol/L) 15.3 (4.1) 14.1 (3.2) 12.5 (3.6)a 11.8 (2.9)a 10.4 (4.0)a,b 0.001
Values are mean ± SD or numbers. BMI, body mass index; HR, heart rate; ASA: acetylsalicylic acid; ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin II receptor
blocker; CCB: calcium channel blocker; SBP, systolic blood pressure; DBP, diastolic blood pressure; LDL, low density lipoprotein; HDL, high density lipoprotein; TB, total bilirubin;
Numerical variables were compared by t-test; Categorical variables (male/female, smoker, medications) were compared by chi-square test. P*-value, control group vs. HFpEF
group; aP< 0.05 compared with control, after Bonferroni correction; bP< 0.05 compared with stage 1-mild, after Bonferroni correction; cP <0.05 compared with stage
2-modeate, after Bonferroni correction; dP< 0.05 compared with stage 3-severe (reversible restrictive), after Bonferroni correction.
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that in the general population, upper normal or modestly
elevated bilirubin levels are associated with improved
outcomes, such as a lower risk of coronary heart disease
events, respiratory disease, and all-cause mortality [20-22].
A previous study showed that serum bilirubin levels were
inversely correlated with the superoxide anion radicals
generated by mononuclear cells in cardiac syndrome X
patients [23]. In 2012, a study on a large statin-treated co-
hort reported that serum bilirubin level measured before a
statin prescription to assess liver function was an inde-
pendent risk factor for cardiovascular disease and death in
both men and women [21]. It showed that the incidence
of cardiovascular disease in the lowest decile category of
bilirubin was 215 per 10,000 person-years compared with
163 per 10,000 person-years in the highest decile. As for
the relationship between bilirubin and HF, the conclu-
sions are still controversial. For example, a recentanalysis of the Efficacy of Vasopressin Antagonism in Heart
Failure Outcome Study with Tolvaptan (EVEREST) cohort,
which included patients hospitalized with systolic HF,
showed that an elevated baseline TB level and in-
hospital increase in bilirubin were associated with an
increased risk of all-cause mortality and combined cardio-
vascular mortality [24]. While in another study which
focused on the relationship between liver function abnor-
malities and hemodynamic profile, it turned out that the
predictors of all-cause mortality were γ-glutamyl transpep-
tidase, alkaline phosphatase, aspartate aminotransferase and
lactic dehydrogenase, other than TB [25]. However, there
were fewer data investigating the relationship between TB
and diastolic dysfunction. In our study, serum TB level in
HFpEF was lower than that in the normal controls, and
serum TB level in grade subgroup 4 was lower than that in
grade subgroup 1. To our knowledge, this is the first study
to investigate the association between serum TB level and
Table 2 Results of univariate and multivariate regression
with stepwise selection estimating TB levels
Varibles Univariate Multivariate
β SE(β) P β SE(β) P
Male 1.62 0.32 0.002 3.47 0.83 0.001
Age 0.06 0.02 0.021 0.09 0.04 0.003
BMI 0.24 0.06 0.375
Smoke -0.57 0.39 0.427
Total cholesterol -0.38 0.14 0.224
HDL cholesterol 0.69 0.41 0.573
LDL cholesterol -0.51 0.10 0.106
Triglyceride 0.82 0.37 0.483
SBP -0.12 0.06 0.504
DBP -0.08 0.14 0.669
Diastolic dysfunction grade -0.92 0.35 0.037 -1.03 0.39 0.021
BMI, body mass index; HDL, high density lipoprotein; LDL, low density lipoprotein;
SBP, systolic blood pressure; DBP, diastolic blood pressure; β, standardized
regression coefficient; SE(β), standard error of the standardized regression
coefficient. Correlation between the continuous variable and TB level was
made by Pearson’s method; correlation between the discrete variable and
TB level was made by Spearman’s method; Multivariate regression model:
αin = 0.05, αout = 0.10, R
2 = 0.261.
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those results might be related to the antioxidant effects of
bilirubin. As we all know, HF may cause hepatic congestion
and reduced forward flow, which would lead to elevated TB
levels, but we found that it was negatively correlated with
the severity of our patients’ LV diastolic dysfunction. This
finding implied that some potential benefits might out-
weigh the underlying severity of HF causing the TB level
increasing. The mechanisms linking low bilirubin and risk
or worse outcomes for cardiovascular disease are not fully
understood. A number of mechanisms has been proposed
for the antioxidant effects of bilirubin, including suppres-
sion of low-density lipoprotein oxidation [26], monocyte
migration [27], vascular smooth muscle cell proliferation
[28] and endothelial dysfunction [29]. Early animal experi-
ments indicated that bilirubin served as a physiological
antioxidant in ischemia–reperfusion [30] and served a
protective function against injury-mediated prolifera-
tion of intimal cells [31]. It was reported that moderate
hyperbilirubinemia reduced blood pressure in angiotensin
II-dependent hypertension through decreasing oxidative
stress and increasing nitric oxide levels [32]. Our study
was only a clinical observation, further experiments are
needed to explore the underlying mechanisms.
Biomarkers of HFpEF
The best characterized biomarkers in patients with HFpEF
are the natriuretic peptides: B-type natriuretic peptide
(BNP) and N-terminal pro-BNP (NT pro-BNP) [29]. BNP
is mainly released in response to increased cardiac volume
and pressure overload. It is synthesized as an inactive pro-hormone that is split into the active hormone BNP and the
inactive NT pro-BNP. Both elevated NT pro-BNP and
BNP are strong independent predictors of clinical events in
patients with HFpEF. No consensus exists on use of natri-
uretic peptide levels to guide medical therapy [33]. Our
study was an attempt to invesigate whether bilirubin might
play an role in the pathogenic processes that link oxidative
stress and diastolic dysfunction in HFpEF patients.Limitations
There were potential limitations to this study. First, the
sample size was relatively small. Further studies with
larger sample sizes are needed to confirm our results.
Second, our study was cross-sectional, and it would have
been ideal to have obtained repeated determinations in
the same patients over time in our study to prove their
relationship.Conclusions
The results of this study indicated a correlation between
decreased serum TB level and increasing severity of LV
diastolic dysfunction in HFpEF. Further in vivo studies
investigating the mechanisms underlying decreased TB in
patients with HFpEF may assist in developing new targets
for prevention and treatment.Methods
Subjects
This observational study included 327 patients (130 male
and 197 female, aging 66.8 ± 10.3 years old) with HFpEF
who were hospitalized in our department during the
period from January 2008 to January 2013 and a normal
control group consisting of 200 healthy volunteers (116
male and 84 female, aging 43.6 ± 9.7 years old) who
attended an annual checkup at our hospital in 2012.
HFpEF was diagnosed according to criteria in the consen-
sus statement of the Heart Failure and Echocardiography
Associations of the European Society of Cardiology [7].
Patients with systolic HF, severe valvular stenosis or regur-
gitation, congenital heart disease, atrial fibrillation, chronic
obstructive pulmonary disease, malignancy, other extracel-
lular fluid-increasing diseases such as hypothyroidism,
diabetes, serious cerebrovascular diseases, a history of liver
or gallbladder or bile-duct disease, hemolytic disease,
rheumatic or immune diseases were excluded. The control
participants had no cardiovascular or any other organ sys-
tem disease, and had normal physical examination, chest
roentgenogram, electrocardiogram, two-dimensional and
Doppler echocardiogram. All participants gave their in-
formed consent, and the study protocol was approved by
ethical review board of Tongji Hospital Affilated to Tongji
University, Shanghai, China.
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5 ml venous blood sample was collected from each partici-
pant under fasting conditions. Then they were centrifuged
and the serum was extracted for use, with spinning speed
800 g for 5 mins at 4°C and storage temperature -80°C.
Fasting blood glucose, total cholesterol, high-density lipo-
protein cholesterol, low-density lipoprotein cholesterol,
triglyceride, uric acid, creatinine and TB levels were re-
corded. TB levels were analyzed using an autoanalyzer
(Roche Diagnostic Modular Systems, Tokyo, Japan).
Echocardiography
All participants underwent complete transthoracic echocar-
diographic studies (Vivid 7 system, General Motor Corp.,
USA) using a 2.5–4.0-MHz transducer. LVEF was measured
using Simpson’s method. The following conventional mitral
inflow pulse wave Doppler parameters were measured: peak
early (E) and late diastolic (A) transmitral filling flow veloci-
ties, E/A ratio, ΔE/A with a Valsalva maneuver and deceler-
ation time (DT) of the E wave and isovolumic relaxation
time (IRT), defined as the time from aortic valve closure to
mitral valve opening. Pulmonary venous flow parameters
were also measured: peak systolic velocity (Ps), peak dia-
stolic velocity (Pd), Ps/Pd ratio, atrial reversal (PVAr) vel-
ocity, the difference in PVAr and transmitral A velocity
duration (PVAr-A). Tissue Doppler parameters were mea-
sured: peak systolic mitral annular velocity (S’), early dia-
stolic mitral annular velocity (E’) and late diastolic mitral
velocity (A’). Those parameters were obtained from the
apical four-chamber view, 1–3-mm sample volume for
mitral leaflets, 2–3-mm for pulmonary vein, 2–5-mm for
mitral leaflets, respectively. The mean of three measure-
ments was used for analysis of the Doppler data. The ratio
of mitral peak velocity of early diastolic filling to early
diastolic mitral annular velocity (E/E’) was calculated for the
lateral and septal annulus. All the HFPEF patients were
divided into four groups: 1 – mild, 2 – moderate, 3 – severe
(reversible restrictive), 4 – severe (fixed restrictive) [14]. 1
(mild): E/A <0.8, ΔE/A (Valsalva maneuver) <0.5, DT >
200 ms, E/E’lateral < 8, Ps > Pd, PVAr-A < 30 ms; 2 (moder-
ate): 0.8 < E/A < 2, ΔE/A (Valsalva maneuver) ≥ 0.5, 160 <
DT< 200 ms, E/E’lateral ≥ 8–12, Ps < Pd, PVAr-A ≥ 30 ms; 3
(severe) (reversible restrictive): E/A ≥ 2, ΔE/A (Valsalva man-
euver) ≥ 0.5, DT < 160 ms, E/ E’lateral > 12, Ps < Pd, PVAr-
A ≥ 30 ms; 4 (severe) (fixed restrictive): E/A ≥ 2, ΔE/A
(Valsalva maneuver) < 0.5, DT < 160 ms, E/ E’lateral > 12,
Ps < Pd, PVAr-A ≥ 30 ms.
Statistical analysis
All statistical analyses were carried out using statistical
software (SPSS, version 15.0 for Windows; SPSS Inc., USA).
All numeric variables were expressed as mean ± SD and
normally distributed. We performed a hierarchal analysis be-
tween two groups (controls and HFpEF) and then a furtheranalysis among 5 groups (Control, 1-mild, 2-moderate, 3-
severe reversible, 4-severe fixed) with Bonferroni-correction.
Numerical variables were compared by t-test and categorical
variables were compared by chi-square test. Simple linear
regression and multivariate regression with stepwise selec-
tion were used to evaluate factors associated with TB levels.
Probability values of P < 0.05 were considered significant.
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